Topping the 11th annual list of Cleveland Clinic’s ‘Top 10 Medical Innovations’ is the harnessing of the microbiome, the gut bacteria swarming in all of us. Recent discoveries have revealed the power of microbes to prevent, diagnose and treat disease. The healthcare industry will soon be pouring resources into addressing the potential for new therapies, diagnostics, probiotics and other products.
DirectorsTalk caught up with Stephen O’Hara the CEO of OptiBiotix Health Plc (LON:OPTI) a company that develops compounds which modify the humanbiome.
Stephen OHara, OptiBiotix Health Plc CEO said: ‘This report from leading US researchers and clinicians presenting at the 2016 Medical Innovation Summit identifies the Top 10 Innovations which they believe have the power to transform healthcare in 2017. Harnessing the power of the microbiome to prevent, manage, and treat disease is number 1 in this list. The report describes 2017 as the year the microbiome cements itself as the healthcare industry’s most promising and lucrative frontier. Key to translating science into a healthcare setting is demonstrating the ability to change the microbiome in a controlled way which improves health. OptiBiotix’s research (as presented at this weeks recent European Microbiome summit) has demonstrated a unique ability to alter the microbiome in a very targeted way, enhancing a particular bacterial species growth, biological activity, and health benefit, and places it at the forefront of this growing revolution in healthcare’.
